Skip to content
Clinical Trials – home

TAFLUPROST: A Comprehensive Guide for Patients

1 / 2
trials open to patients / all trials
2+
Countries

In short

Tafluprost is a prostaglandin analog medication used in the treatment of glaucoma and ocular hypertension. This article examines various clinical trials investigating the efficacy, safety, and tolerability of Tafluprost, particularly in comparison to other treatments and in preservative-free formulations. These studies aim to evaluate Tafluprost's ability to lower intraocular pressure (IOP) and its effects on ocular surface health in patients with glaucoma and ocular hypertension.

At a glance

Drug Name
Tafluprost
Primary Use
Treatment of glaucoma and ocular hypertension
Mechanism
Lowers intraocular pressure (IOP)
Administration
Eye drops, typically once daily in the evening
Formulations
Preserved and preservative-free
Key Benefits
Effective IOP reduction, potentially less ocular surface irritation (preservative-free)
Comparisons
Often compared to latanoprost in clinical trials
Study Durations
Ranging from 3 months to 12 months
Outcome Measures
IOP reduction, ocular surface health, patient comfort, quality of life
Special Considerations
Potential benefits for patients with ocular surface disease or preservative sensitivity

What is Tafluprost?

Tafluprost is a medication used in the treatment of eye conditions, primarily glaucoma and ocular hypertension. It belongs to a class of drugs called prostaglandin analogs, which are commonly used to lower eye pressure. Tafluprost is available under various brand names, including Saflutan, Taflotan, and Zioptan.

What Conditions Does Tafluprost Treat?

Tafluprost is primarily used to treat two main eye conditions:

  • Primary Open-Angle Glaucoma (POAG): This is the most common type of glaucoma, where the drainage channels in the eye become slowly clogged over time, leading to increased eye pressure.
  • Ocular Hypertension (OHT): This condition is characterized by higher than normal pressure inside the eye, without any detectable changes in vision or damage to the eye structure.

Both of these conditions can lead to vision loss if left untreated, which is why medications like Tafluprost are crucial in managing eye health.

How Does Tafluprost Work?

Tafluprost works by reducing the pressure inside the eye, also known as intraocular pressure (IOP). It does this by increasing the natural outflow of fluid from inside the eye. By lowering the eye pressure, Tafluprost helps prevent damage to the optic nerve and preserves vision.

How is Tafluprost Administered?

Tafluprost is typically administered as eye drops. The usual dosage is one drop in the affected eye(s) once daily, usually in the evening. It's important to follow your doctor's instructions precisely. Some key points about administration include:

  • Tafluprost is often prescribed as a 0.0015% solution.
  • It's usually administered once daily, often at around 8:00 PM or 9:00 PM.
  • The medication comes in single-dose containers to ensure proper dosage and reduce contamination risk.

Effectiveness of Tafluprost

Clinical trials have shown that Tafluprost is effective in reducing intraocular pressure in patients with glaucoma or ocular hypertension. Some studies have focused on its 24-hour efficacy, meaning it can maintain lower eye pressure throughout the day and night.

In one study, Tafluprost was found to be effective in patients with high intraocular pressure (30 mmHg or more), demonstrating its potency in managing severe cases.

Preservative-Free Tafluprost

One of the unique features of Tafluprost is that it's available in a preservative-free formulation. This is particularly beneficial for patients who may be sensitive to preservatives commonly used in eye drops. The preservative-free version may cause less irritation and be better tolerated, especially in patients with ocular surface disease or dry eye symptoms.

Potential Side Effects and Ocular Surface Health

While Tafluprost is generally well-tolerated, it may cause some side effects. These can include:

  • Eye redness
  • Itching
  • Irritation or burning sensation
  • Changes in eyelash appearance (they may become longer, thicker, or darker)

Several studies have investigated the effects of Tafluprost on ocular surface health. These studies have looked at factors such as tear film stability, corneal staining (a measure of corneal damage), and overall eye comfort. The preservative-free formulation of Tafluprost has shown potential benefits in maintaining ocular surface health, especially when compared to preservative-containing eye drops.

Comparisons with Other Medications

Several studies have compared Tafluprost to other glaucoma medications, particularly Latanoprost, another commonly used prostaglandin analog:

  • Some studies have found Tafluprost to be as effective as Latanoprost in lowering intraocular pressure.
  • Patients switching from Latanoprost to preservative-free Tafluprost often experienced improvements in ocular surface symptoms and signs.
  • In some cases, Tafluprost has been used in combination with other glaucoma medications (like Timolol) for enhanced pressure-lowering effects.

It's important to note that the choice of medication depends on individual patient factors, and your eye doctor will determine the best treatment plan for your specific situation.

Questions people often ask

Conditions where Tafluprost is being studied

Each condition opens its own overview and trial list

Trials with Tafluprost

Recruiting trials first

See all 2 →
Quick filters
  • Participants:Adults
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.

Legal notice · Published by CTIN POLAND sp. z o.o., ul. rtm. Witolda Pileckiego 67/109, 02-781 Warsaw, Poland · KRS 0001111334 · REGON 528919042 · NIP 9512598637

© 2026 Clinical Trials EU – European Clinical Trials Information Network

GDPR compliance, ISO 9001 and ISO 27001 certified (LL-C Certification)

On this site, “treatment” means an investigational medicine being studied in a clinical trial. Its safety and efficacy for the use being studied have not yet been confirmed, some participants may receive a placebo or a comparator medicine, and taking part does not guarantee any health benefit. The decision to take part is made by the doctor at the research site. This site is for information only and does not replace medical advice.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic sites, national regulators and commercial sponsors. On this site, “treatment” and “therapy” mean a medicine being tested in a clinical trial. Its safety and effectiveness in the use being studied are not yet confirmed, some participants may receive a placebo or a comparator, and taking part does not guarantee a health benefit. The doctor at the research site decides who can take part. This site provides information, not medical advice. Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).